Spain transposes EU blood products directive:
This article was originally published in Clinica
Spain has transposed EU legislation that regulates medical products containing stable products from human blood or plasma. Royal Decree 710/2002 replaces Royal Decree 414/1996, after the EU amended directive 2000/70/CE with directive 2001/104/CE due to a translation error that exempted products derived from blood and plasma from the medical device regulations (see Clinica No 992, p 3). The new decree, which was approved on July 19, over a month after its due transposition date, will be enforced gradually: products regulated by it may be sold only until December 13 2005 and must be used before December 13 2007.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.